Zou M, Shi Y, Farid N R, al-Sedairy S T, Paterson M C
Department of Biological and Medical Research (MBC-03), King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Eur J Cancer. 1999 Mar;35(3):467-72. doi: 10.1016/s0959-8049(98)00370-0.
FHIT, a candidate tumour suppressor gene, has recently been identified at chromosomal region 3p14.2, and deletions of the gene have been reported in many types of human cancers. Loss of heterozygosity (LOH) at this region has also been found frequently in follicular thyroid carcinoma (FTC). To investigate the potential role of FHIT in thyroid tumorigenesis, we examined 57 thyroid tumour specimens (eight benign adenomas, 40 papillary, four follicular and five anaplastic carcinomas), and two thyroid carcinoma cell lines (NPA, SW579) for genetic alterations by using reverse transcription-polymerase chain reaction (RT-PCR), PCR product sequencing, single-strand conformation polymorphism (SSCP) and Southern blot analysis. Two cervical carcinoma cell lines (C-33A, HeLa) were included as positive controls. We detected truncated FHIT transcripts in three of eight (38%) benign adenomas, nine of 40 (23%) papillary, and two of five (40%) anaplastic carcinomas, and in three cell lines (SW579, C-33A, HeLa). Most of the truncated transcripts lacked exons 4 or 5 to 7 or 8 of the gene and were presumably non-functional as the translation start site is located in exon 5. SSCP analysis of the coding exons failed to detect any point mutations among the samples without abnormal FHIT transcripts. Southern blot analysis demonstrated either loss or reduced intensity of major Bam HI restriction fragments in the three cell lines found to have abnormal FHIT transcripts, indicating, respectively, either intragenic homozygous or heterozygous deletions of the FHIT gene. Intragenic homozygous deletions were also found in two papillary thyroid carcinoma specimens: one was missing a 13 kb Bam HI fragment which contains exon 4, the other had deletions of 15.5, 13 and 4.2 kb fragments which contain exons 2 and 9, 4, and 5, respectively. The absence of a defective FHIT gene in FTC indicates that an additional tumour suppressor gene may reside in this region and be involved in the development of FTC. Given that defective FHIT genes were found in both benign and malignant thyroid tumours, the inactivation of this putative tumour suppressor gene is likely to be an early event in the pathogenesis of some forms of thyroid neoplasms.
FHIT是一种候选肿瘤抑制基因,最近在染色体区域3p14.2被发现,该基因的缺失已在多种人类癌症中报道。在滤泡状甲状腺癌(FTC)中也经常发现该区域的杂合性缺失(LOH)。为了研究FHIT在甲状腺肿瘤发生中的潜在作用,我们使用逆转录-聚合酶链反应(RT-PCR)、PCR产物测序、单链构象多态性(SSCP)和Southern印迹分析,检测了57例甲状腺肿瘤标本(8例良性腺瘤、40例乳头状癌、4例滤泡状癌和5例未分化癌)以及2株甲状腺癌细胞系(NPA、SW579)的基因改变。将2株宫颈癌细胞系(C-33A、HeLa)作为阳性对照。我们在8例良性腺瘤中的3例(38%)、40例乳头状癌中的9例(23%)、5例未分化癌中的2例(40%)以及3株细胞系(SW579、C-33A、HeLa)中检测到截短的FHIT转录本。大多数截短的转录本缺少该基因的外显子4或5至7或8,由于翻译起始位点位于外显子5,推测这些转录本无功能。对编码外显子的SSCP分析未能在无异常FHIT转录本的样本中检测到任何点突变。Southern印迹分析显示,在发现有异常FHIT转录本的3株细胞系中,主要Bam HI限制性片段出现缺失或强度降低,分别表明FHIT基因发生了基因内纯合或杂合缺失。在2例乳头状甲状腺癌标本中也发现了基因内纯合缺失:1例缺失了一个包含外显子4的13 kb Bam HI片段,另1例分别缺失了包含外显子2和9、4以及5的15.5、13和